F. Spriano

Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity

This study identifies HERV-K as a therapeutic target in DLBCL, develops a humanized nanobody with anti-lymphoma activity, and shows its potential through antibody-dependent cytotoxicity.

Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents

This study evaluates the anti-lymphoma activity of camidanlumab tesirine as a single agent and in combination with targeted agents in various lymphoma cell lines.

The ATR inhibitor elimusertib exhibits anti-lymphoma activity and synergizes with the PI3K inhibitor copanlisib

This paper shows that elimusertib, an ATR inhibitor, has anti-lymphoma activity and synergizes with copanlisib, a PI3K inhibitor, in multiple lymphoma models.

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

This study identifies ERBB4-mediated signaling as a mechanism of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms and shows that targeting ERBB signaling can restore sensitivity.

Assessment of lisavanbulin (BAL101553) as an anti-lymphoma agent

This study evaluates lisavanbulin's anti-lymphoma activity and EB1 expression in DLBCL, showing potent in vitro cytotoxicity and potential clinical relevance.

A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers

This paper develops EG-011, a first-in-class WASp activator with anti-tumor activity in hematological cancers, including resistant models.

Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer

This study shows that SPOP and ERG mutations in prostate cancer have opposing effects on androgen receptor signaling and therapy response.